| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-12-15 | Vect-Horus (France) | € 1.5 million | fundraising | BpiFrance (France) | Technology - Services - Cardiovascular diseases - Cerebrovascular diseases | Fundraising |
| 2014-12-10 | Genfit (France) | € 21 million | private placement | Metabolic diseases - Liver diseases | Private placement | |
| 2014-12-09 | Novacyt (France) | €3.1 million | private placement | Alto Invest (France), new and existing Novacyt investors | Cancer - Oncology - Infectious diseases - Diagnostic | Private placement |
| 2014-12-08 | Quantum Genomics (France) | € 3 million | fundraising | Cardiovascular diseases | Fundraising | |
| 2014-12-05 | Molecular Partners (Switzerland) | CHF 106.2 million | IPO | Cancer - Oncology - Ophtalmological diseases | IPO | |
| 2014-12-03 | Pledpharma (Sweden) | 75 million SEK (€8.1 million) | private placement | Private placement | ||
| 2014-12-03 | Anergis (Switzerland) | CHF 14.5 Million (€ 12.1 million) | series B financing round | Vinci Capital-Renaissance PME (Switzerland) BioMedInvest (Switzerland) Sunstone Capital ( Denmark) Esperante (Sweden) Initiative Capital Romandie (Switzerland) WJFS (USA) | Allergic diseases - Immunological diseases | Series B financing round |
| 2014-12-03 | Oramed Pharmaceuticals (Israel) | $5 million | private placement | Guangxi Wuzhou Pharmaceutical Company (China) | Private placement | |
| 2014-12-02 | Xeltis (Switzerland) | €27 million | series B financing round | Life Sciences Partners (LSP) (The Netherlands), Kurma Partners (France), VI Partners (Switzerland) and current shareholders of Xeltis | Cardiovascular diseases - Medical devices | Series B financing round |
| 2014-12-02 | AyoxxA Biosystems (Germany) | € 11.3 million | series B financing round | Wellington Partners Venture Capital (Germany), NRW.BANK (Germany), HTGF - High-Tech-Gründerfonds (Germany), KfW (Germany), b-to-v Partners (Germany), Creathor Venture (Germany), HR Ventures (Germany), private investors from the US and Europe, including Ayoxxa employees and two of Qiagen’s founders, BioMedPartners (Switzerland), Grazia Equity (Germany) | Technology - Services - Diagnostic | Series B financing round |
| 2014-12-02 | Audentes Therapeutics (USA - CA) | $42.5 million | series B financing round | Sofinnova Ventures (USA - CA) Venrock (USA - CA) OrbiMed (USA - NY) 5AM Ventures (USA - CA) Versant Ventures (USA - CA) | Rare diseases - Genetic diseases | Series B financing round |
| 2014-12-01 | Medgenics (Israel - USA) | $24.2 million | private placement | Genetic diseases - Pediatric diseases - Rare diseases | Private placement | |
| 2014-11-25 | Promethera Biosciences (Belgium) | €25.33 million ($31.4 million) | series C financing round | SFPI-FPIM (Belgium) SMS Investments (Luxemburg - Germany) Vesalius Biocapital Partners (Luxemburg) SRIW (Belgium) Boehringer Ingelheim Venture Fund (Germany) Shire (UK - USA) Mitsui Global Investment (Japan) ATMI (USA) SambrInvest (Belgium) Walloon Region (Belgium) Pall-ATMI LifeSciences (USA - MN) Vives-Louvain Technology Transfer Office Fund (Belgium) business angels. | Rare diseases - Genetic diseases - Metabolic diseases - Liver diseases | Series C financing round |
| 2014-11-25 | Cell Medica (UK) | £50 Million (€ 31.5 million) | series B financing round | Imperial Innovations (UK) Invesco Perpetual (UK) Woodford Investment Management (UK) | Cancer - Oncology - Infectious diseases | Series B financing round |
| 2014-11-25 | Nanobiotix (France) | up to $25 million | private placement | Capital Ventures International (USA) | Cancer - Oncology | Private placement |
| 2014-11-24 | Orgenesis SPRL (Belgium) Orgenesis (USA - NY) | € 2,015 million | grant | Walloon Region (Belgium) | Metabolic diseases | Grant |
| 2014-11-20 | Modern Biosciences (UK) | £2.4 million (€3 million) | grant | Biomedical Catalyst Fund (UK) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Grant |
| 2014-11-20 | Heptares (UK) | £1.5 million (€1.8 million) | grant | Biomedical Catalyst Fund (UK) | Metabolic diseases - Rare diseases | Grant |
| 2014-11-19 | Cempra (USA - NC) | $16 million | grant | Biomedical Advanced Research and Development Authority (USA) | Infectious diseases | Grant |
| 2014-11-18 | Intellia Therapeutics (USA - MA) | $15 million | series A financing round | Atlas Venture (USA - MA) Novartis (Switzerland) | Technology - Services | Series A financing round |
